Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Sci Rep. 2024 Jul 10;14(1):15960. doi: 10.1038/s41598-024-65943-z.
Non-invasive imaging of GSK-3 expression in the brain will help to understand the role of GSK-3 in disease pathology and progression. Herein, we report the radiosynthesis and evaluation of two novel isonicotinamide based F labeled PET probes, [F]2 and [F]6 for noninvasive imaging of GSK3. Among the developed PET probes, the in vitro blood-brain permeability coefficient of 2 (38 ± 20 × 10 cm/s, n = 3) was found to be better than 6 (8.75 ± 3.90 × 10 cm/s, n = 5). The reference compounds 2 and 6 showed nanomolar affinity towards GSK-3α and GSK-3β. PET probe [F]2 showed higher stability (100%) in mouse and human serums compared to [F]6 (67.01 ± 4.93%, n = 3) in mouse serum and 66.20 ± 6.38%, n = 3) in human serum at 120 min post incubation. The in vivo imaging and blocking studies were performed in wild-type mice only with [F]2 due to its observed stability. [F]2 showed a SUV of 0.92 ± 0.28 (n = 6) in mice brain as early as 5 min post-injection followed by gradual clearance over time.
非侵入性成像技术可用于研究 GSK-3 在大脑中的表达,这将有助于我们了解 GSK-3 在疾病发病机制和进展中的作用。本文报道了两种新型异烟酰胺基 F 标记的 PET 探针[F]2和[F]6的放射性合成和评价,用于非侵入性成像 GSK3。在开发的 PET 探针中,2 的体外血脑屏障渗透率(38±20×10 cm/s,n=3)优于 6(8.75±3.90×10 cm/s,n=5)。参考化合物 2 和 6 对 GSK-3α和 GSK-3β表现出纳摩尔亲和力。与 [F]6 相比(在小鼠血清中 67.01±4.93%,n=3,在人血清中 66.20±6.38%,n=3),[F]2 在小鼠血清中具有更高的稳定性(100%),在 120 分钟孵育后。由于观察到的稳定性,仅在野生型小鼠中进行了 [F]2 的体内成像和阻断研究。[F]2 在注射后 5 分钟即可在小鼠大脑中达到 0.92±0.28 的 SUV(n=6),随后逐渐清除。